Equities analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to announce sales of $290,000.00 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $320,000.00 and the lowest is $250,000.00. Alpine Immune Sciences reported sales of $320,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 9.4%. The company is scheduled to announce its next quarterly earnings results on Monday, May 13th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year sales of $1.13 million for the current fiscal year, with estimates ranging from $1.00 million to $1.26 million. For the next financial year, analysts forecast that the business will post sales of $1.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Get Alpine Immune Sciences alerts:

Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Monday, March 18th. The biotechnology company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80).

A number of analysts have recently weighed in on the stock. Oppenheimer set a $13.00 price target on shares of Alpine Immune Sciences and gave the company a “buy” rating in a report on Tuesday, March 19th. ValuEngine upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a report on Tuesday, March 26th. Finally, restated a “buy” rating and issued a $13.00 price target on shares of Alpine Immune Sciences in a report on Tuesday, February 12th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Alpine Immune Sciences presently has a consensus rating of “Buy” and a consensus price target of $12.07.

Shares of NASDAQ:ALPN traded down $0.45 during trading on Tuesday, reaching $6.75. The stock had a trading volume of 23,570 shares, compared to its average volume of 15,783. Alpine Immune Sciences has a one year low of $3.66 and a one year high of $10.57. The stock has a market capitalization of $99.75 million, a P/E ratio of -2.57 and a beta of 2.13. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.59 and a current ratio of 6.59.

In other news, major shareholder Tiger Management L.L.C. sold 25,000 shares of the firm’s stock in a transaction dated Friday, February 8th. The shares were sold at an average price of $5.85, for a total value of $146,250.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 69.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in ALPN. Hikari Power Ltd acquired a new stake in Alpine Immune Sciences in the 4th quarter worth approximately $453,000. Victory Capital Management Inc. boosted its stake in Alpine Immune Sciences by 109.0% in the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares in the last quarter. Vanguard Group Inc. boosted its stake in Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares in the last quarter. Finally, Vanguard Group Inc boosted its stake in Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares in the last quarter. Institutional investors own 53.79% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.